Minsig Choi, MD, Stony Brook University Hospital

home / authors / minsig-choi,-md,-stony-brook-university-hospital

Articles

Emerging Therapies for HCC Management

Emerging Therapies for HCC Management

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Metastatic HCC Unmet Needs

Metastatic HCC Unmet Needs

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

I/O Second-Line Treatment

I/O Second-Line Treatment

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

REACH and REACH2 Trial Overview

REACH and REACH2 Trial Overview

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Second-Line Therapy: Monoclonal Antibody

Second-Line Therapy: Monoclonal Antibody

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Second-Line Sequencing After IMbrave150 Regimen

Second-Line Sequencing After IMbrave150 Regimen

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

R/R HCC: Second-Line Options

R/R HCC: Second-Line Options

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Frontline I/O: Clinical Trial Overviews

Frontline I/O: Clinical Trial Overviews

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Frontline Therapy: Promising I/O Combinations

Frontline Therapy: Promising I/O Combinations

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Phase 3 IMbrave150 Trial

Phase 3 IMbrave150 Trial

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Frontline Decision Factors for Metastatic Disease

Frontline Decision Factors for Metastatic Disease

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

HCC Treatment Algorithm: Asia and Europe

HCC Treatment Algorithm: Asia and Europe

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Transitioning From Locoregional to Systemic Therapy

Transitioning From Locoregional to Systemic Therapy

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

HCC Diagnosis and Prognosis

HCC Diagnosis and Prognosis

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

The Evolving Role of Medical Oncologists and Hepatologists

The Evolving Role of Medical Oncologists and Hepatologists

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

HCC Global Screening Programs for At-Risk Populations

HCC Global Screening Programs for At-Risk Populations

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

HCC Etiologic Risk Factors and Global Prevalence

HCC Etiologic Risk Factors and Global Prevalence

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need